Compositions for a dietary supplement to manage senescent cells
US-2024390346-A1 · Nov 28, 2024 · US
Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof
US8962017B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8962017-B2 |
| Application number | US-200913126071-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 23, 2009 |
| Priority date | Dec 31, 2008 |
| Publication date | Feb 24, 2015 |
| Grant date | Feb 24, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.94 times longer; when tested in vivo in Beagle dogs, this new formulation of silymarin presents a smoother concentration-time curve and reaches a continuous release for 72 hours. This invention discloses its preparation method.
First claim
Opening claim text (preview).
What is claimed is: 1. A formulation of silymarin, comprising: a silymarin solid dispersion, silymarin-loaded silica nanoparticles, a slow-release matrix material and a release enhancer, wherein a mass ratio of the silymarin solid dispersion:the silymarin-loaded silica nanoparticles:the slow-release matrix material:the release enhancer is 1:0.5-1.25:0.1-0.3:0.1-0.3; wherein the silica nanoparticles are a mesoporous material including a plurality of pores having a diameter of 1.5…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8962017B2 cover?
- A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the…
- Who is the assignee on this patent?
- Xu Ximing, Yu Jiangnan, Tong Shanshan, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/357. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).